Patent controversy embroils South Korean biotech claiming key CRISPR IP
Questions emerge about whether ToolGen properly acquired foundational gene editing patents, and how much government support founder Kim Jin-soo received for his breakthrough invention.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.